Showing results (131-140 of 229) with videos related to

Sort By:
Pageof 23
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 23, 2013
The rs1800716 variant in CYP2D6 is associated with an increased double endometrial thickness in postmenopausal women on tamoxifenA-S Dieudonné, D Lambrechts, D Smeets, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 16, 2000
Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrumentC Tropé, J Kaern, T Hogberg, et al.
Gynecologic Oncology|April 16, 2021
Safety and efficiency of performing transvaginal ultrasound-guided tru-cut biopsy for pelvic massesH Verschuere, W Froyman, T Van den Bosch, et al.
European Journal of Cancer (Oxford, England : 1990)|January 2, 2013
Long-term results of weekly paclitaxel carboplatin induction therapy: an effective and well-tolerated treatment in patients with platinum-resistant ovarian cancerM E L van der Burg, I Vergote, W Onstenk, et al.
Revue Medicale De Liege|January 8, 2016
[Belgian register and reference centers for gestational trophoblastic diseases]S Delcominette, M Timmermans, K Delbecque, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|December 3, 2020
Robot-assisted surgery for women with endometrial cancer: Surgical and oncologic outcomes within a Belgium gynaecological oncology group cohortA Kakkos, C Ver Eecke, S Ongaro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 16, 2004
Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patientsL Morales, D Timmerman, P Neven, et al.
Breast Cancer Research and Treatment|May 17, 2018
Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancerG Hoste, K Punie, H Wildiers, et al.
European Journal of Cancer (Oxford, England : 1990)|June 12, 2009
Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancerI Vergote, N Finkler, J del Campo, et al.
Gynecologic Oncology|April 2, 2002
PTEN mutations in uterine sarcomasF Amant, M de la Rey, C M Dorfling, et al.
Pageof 23